# Strategies for Monitoring Serum Protein Degradation With an Antibody Array‐Based Technology

**Authors:** Yanlin Wang, Min Lang, Wei Huang, Siwei Zhu, Yingqing Mao, Shuhong Luo, Hua Dong, Ruo‐Pan Huang

PMC · DOI: 10.1002/jcla.70173 · Journal of Clinical Laboratory Analysis · 2026-02-13

## TL;DR

The study shows that antibody arrays can detect serum protein degradation over time, identifying proteins that rapidly degrade at room temperature.

## Contribution

The study introduces antibody arrays as a feasible tool for monitoring serum protein degradation and identifies potential biomarkers for sample quality assessment.

## Key findings

- 201 out of 480 proteins showed significant degradation over 48 hours at room temperature.
- Degraded proteins were associated with lower molecular weight and key signaling pathways like JAK–STAT and MAPK.
- Rapidly degrading proteins include clinically relevant interleukins, growth factors, and chemokines.

## Abstract

Human serum is an ideal body fluid for discovering and monitoring biomarkers for disease diagnosis and treatment response. However, intrinsic proteolytic degradation during sample handling may compromise biomarker integrity, which may affect the accuracy of results. To address this issue, we aimed to test the feasibility of using antibody array technology to evaluate the temporal stability of serum proteins at room temperature.

Concentrations of 480 serological proteins were monitored using antibody arrays in samples from 10 healthy donors incubated at 25°C for 0, 6, 12, 24, and 48 h. Linear regression assessed time‐dependent concentration changes. Physicochemical properties (molecular weight, isoelectric point, instability index, aliphatic index, hydropathicity) of the proteins were analyzed. Enrichment analyses were performed on degraded proteins.

During 48‐h incubation, 201 proteins showed a significant negative linear correlation between concentration and time, among which the concentration of 91 proteins reduced over 20% in the first 6 h. Degraded proteins were significantly associated with lower molecular weight (MW < 40 kDa) but no other physicochemical properties. Enrichment analyses revealed degraded proteins associated with various terms and involved in important signaling pathways, like JAK–STAT, PI3K‐Akt, and MAPK.

Our data demonstrate the feasibility of employing antibody arrays for detecting serum protein degradation. Using this platform, we found some serum proteins with clinical significance rapidly degrade at room temperature, including interleukins (e.g., IL‐1β/IL‐12p40/IL‐17), growth factors (e.g., aFGF, bFGF, and BMP‐2), and chemokines (e.g., I‐309, 6Ckine, and BLC). These may serve as potential biomarkers for assessing human serum sample quality.

This study analyzed the stability of 480 proteins in human serum samples collected from 10 healthy donors and incubated at room temperature for 0–48 h. Antibody array profiling revealed significant time‐dependent degradation of 201 proteins. Subsequent physicochemical and functional enrichment analyses demonstrated that the degraded proteins were associated with specific structural properties and biological pathways. These findings validate the utility of antibody arrays in monitoring proteolytic degradation and suggest potential biomarkers for assessing serum sample quality in laboratory and clinical diagnostics.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), Il12b (interleukin 12b), IL17A (interleukin 17A), FGF1 (fibroblast growth factor 1), FGF2 (fibroblast growth factor 2), BMP2 (bone morphogenetic protein 2), CCL1 (C-C motif chemokine ligand 1), CCL21 (C-C motif chemokine ligand 21), CXCL13 (C-X-C motif chemokine ligand 13)

## Full-text entities

- **Genes:** CXCL13 (C-X-C motif chemokine ligand 13) [NCBI Gene 10563] {aka ANGIE, ANGIE2, BCA-1, BCA1, BLC, BLR1L}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346] {aka I-309, P500, SCYA1, SISe, TCA3}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, FGF1 (fibroblast growth factor 1) [NCBI Gene 2246] {aka AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-1}, CCL21 (C-C motif chemokine ligand 21) [NCBI Gene 6366] {aka 6Ckine, CKb9, ECL, SCYA21, SLC, TCA4}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13042801/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13042801/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC13042801/full.md

---
Source: https://tomesphere.com/paper/PMC13042801